Last updated: April 24, 2026
What is CL2013003630 and what does it protect?
CL2013003630 is a Chilean patent application (publication/identification “CL2013003630”) filed and published in the 2013 patent cycle. It is part of Chile’s national phase and/or domestic publication system for pharmaceutical inventions.
However, no complete bibliographic record, claim text, or legal status content is provided in the prompt. Without the patent publication page text (title, applicant, abstract), the claim set, and the cited prior art/patent family members, a full scope and claims analysis cannot be produced to a “hard data” standard.
What claims define the patent scope?
A claim-by-claim scope map requires the actual CL2013003630 claim language. That language is not included in the prompt. Without it, it is not possible to:
- identify independent claim boundaries,
- determine dependent claim fallbacks,
- map key limitations (compound, salt, polymorph, dosing regimen, formulation, biomarkers, targets, manufacturing method),
- or infer enforceable subject matter breadth.
How broad is the protection (composition, method, use, or formulation)?
Breadth in pharmaceuticals depends on whether the claims are framed as:
- a chemical entity (compound Markush-type structure),
- a specific salt/solvate/polymorph,
- a formulation (excipients, particle size, release profile),
- a dosing regimen (mg/day, schedule, patient subgroup),
- or a method of treatment/medical use (indication and mechanism).
None of those claim attributes are available for CL2013003630 in the prompt, so the scope breadth cannot be established without inventing facts.
What does the prior-art landscape look like for CL2013003630?
A patent landscape requires at least one of the following:
- cited documents in CL2013003630,
- the patent family (priority application and counterpart jurisdictions),
- or the chemical/biologic target and indication.
The prompt does not include any of these inputs. A prior-art and freedom-to-operate map cannot be constructed without the underlying invention details.
Which competitors are most exposed?
Competitor identification in Chile for a specific application depends on:
- same active ingredient and same claim coverage in counterpart patents,
- same indication and regimen coverage,
- and whether Chile has granted patents or only applications.
No applicant, active ingredient, indication, or claim elements are present in the prompt. A credible competitive exposure analysis cannot be completed.
Legal status and enforceability in Chile
Enforceability in Chile depends on:
- whether CL2013003630 matured into a granted patent,
- whether it is lapsed or under opposition/annulment,
- and whether any SPC-like extensions, regulatory exclusivities, or local availability barriers apply.
No status data is provided, and no claim text is provided to align status with scope.
Practical implications for investors and R&D
For pharma diligence, CL2013003630 would be triaged on:
- core claim independence (compound vs formulation vs method),
- whether claim limitations are structural or functional,
- and whether later amendments narrowed scope during examination.
That triage cannot be performed without the claim set and prosecution record.
Key Takeaways
- CL2013003630’s scope and enforceable claim boundaries cannot be analyzed to an evidence-based standard because the prompt contains no bibliographic data, claim text, abstract, applicant/title, cited prior art, or legal status.
- A defensible Chile patent landscape (family mapping, competitor exposure, and FTO-relevant overlaps) also cannot be constructed without the invention identifiers and claim elements.
- No actionable competitive or R&D guidance can be produced without the underlying patent record.
FAQs
-
What documents are required to analyze CL2013003630 claims accurately?
The patent’s publication/bibliographic page and the full claim text (including all independent and dependent claims), plus legal status or family counterparts.
-
How does Chile scope interpretation affect infringement risk for drug patents?
It depends on whether claims focus on compound/formulation versus medical use or method steps, and on claim construction during examination and enforcement.
-
How do counterpart patents change the Chile landscape?
Counterparts (EP/US/WO) often reveal priority scope, amended claims, and the claim breadth the applicant is willing to defend.
-
What is the fastest way to identify the relevant active ingredient for landscape mapping?
The title/abstract and independent claim structure (compound, target, or indication).
-
Can a landscape be done without knowing the indication and target?
Not reliably, because competitor overlap in pharma is indication- and mechanism-specific.
References
[1] Chilean patent record CL2013003630 (publication details and claim set). (Not provided in the prompt.)
